HILL: the efficacy and safety of hepatic arterial infusion chemotherapy with the FOLFOX regimen combined with lenvatinib and the PD-L1 inhibitor durvalumab in unresectable hepatocellular carcinoma: a prospective, single-arm, phase 2 clinical trial.

Signal Transduct Target Ther · 2026 · PMC13176320 · PMID 42135293

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

showed a trendp = 0.13not close (p > 0.1)

This cohort showed a trend toward longer median PFS (not reached vs. 15.8 months; both p = 0.13) and a higher 2-year overall survival rate (100% vs. 92.6%; p = 0.46) than those who did not receive surgery (Supplementary Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.